Vera Therapeutics Inc, based in Brisbane, California, is a biotechnology firm dedicated to creating innovative treatments for severe immunological diseases. With a focus on research and development, its flagship product, atacicept, is a pioneering fusion protein aimed at treating immunoglobulin A nephropathy and lupus nephritis through subcutaneous injections in advanced clinical trials. Additionally, Vera is working on MAU868, a monoclonal antibody designed to combat BK viremia infections, showcasing its commitment to addressing unmet medical needs in immunology.

VERA Articles